Three people overlooking the ocean at sunrise
Home / Support & resources / Resources

Helpful tools for your practice and patients

Prescribing resources

Important information for prescribing and what patients need to know.

psp enrollment form
BRINSUPRI Prescription and inLighten® Enrollment Form

With this form, you can prescribe BRINSUPRI and help your patients enroll in the inLighten Patient Support program.

Download formdownload icon
Getting Patients Started Brochure
Getting Started Guide for BRINSUPRI

Specifically designed for office staff, this guide details how to get your patients started on BRINSUPRI.

Download guidedownload icon
Patient Information for BRINSURPI
Patient Information for BRINSUPRI 

Important information about BRINSUPRI in patient-friendly language.

Download Patient PDFdownload icon
Prescribing Information for BRINSUPRI
Prescribing Information (PI) for BRINSUPRI

A summary of essential information on BRINSUPRI, including dosing, safety, and efficacy.

Download PIdownload icon

Access resources

Forms you may need to get your patients started with BRINSUPRI.

Sample letters of medical necessity/exception and appeal
BRINSUPRI Sample Letters of Medical Necessity/ Exception and Appeal

Sample letters of medical necessity/exception and appeal that can be modified based on a prescriber's medical judgment and discretion, including details related to the patient's medical history, diagnosis, and treatment plan. Insurance providers may have specific criteria, forms, or procedures that should be used for the prior authorization process.

Download lettersdownload icon
Sample letters of medical necessity/exception and appeal (Spanish)
BRINSUPRI Sample Letters of Medical Necessity/ Exception and Appeal (Spanish)

Cartas de muestra de necesidad/excepción médica y apelació que pueden modificarse según el criterio y juicio medico del prescriptor, incluyendo detalles relacionados con la historia médica del paciente, diagnóstico y plan de tratamiento. Los proveedores de seguros pueden tener criterios específicos, formularios o procedimientos que deben usarse para el proceso de autorizatión previa.

Download lettersdownload icon
Sign up to get the latest information on BRINSUPRI
Get updates

Patient resources

Helpful information to share with your patients.

BRINSUPRI patient brochure
BRINSUPRI brochure

This resource helps patients learn more about BRINSUPRI, including how it works and what to expect as they start treatment.

Download brochuredownload icon
Bronchiectasis management tool brochure
Bronchiectasis Management Tool

This tool helps patients start conversations with their pulmonologists about their bronchiectasis management plan and BRINSUPRI.

Download tooldownload icon
Spanish Brinsupri brochure
BRINSUPRI brochure (Spanish)

This resource helps patients learn more about BRINSUPRI, including how it works and what to expect as they start treatment.

This version of the BRINSUPRI brochure is provided in Spanish.

Download brochuredownload icon

EHR patient identification resources

Guides to help you operate within different EHR systems.

Epic brochure
Epic®: Patient Identification Guide

A detailed guide for generating a patient list within the Epic EHR to identify individuals diagnosed with non-cystic fibrosis bronchiectasis.

Download guidedownload icon
Oracle Brochure
Oracle Health®: Patient Identification Guide

A detailed guide for generating a patient list within the Oracle Health EHR to identify individuals diagnosed with non-cystic fibrosis bronchiectasis.

Download guidedownload icon

Video library

BRINSUPRI in bronchiectasis: Insights for clinical practice

In this National Broadcast recording, experts discuss the role of BRINSUPRI in bronchiectasis management. The panel highlights patient selection and real-world insights to inform treatment decisions.

Speakers: Diego Maselli, MD – University of Texas Health Science Center; Richard Belkin, MD – Santa Barbara Cottage Hospital; Sam Bellinger, APRN – INTEGRIS Health Medical Group; Rajat Walia, MD — St. Joseph's Hospital

Faculty are paid speakers for Insmed.

The mechanism of action of BRINSUPRI


EHR=electronic health record.

Have questions about BRINSUPRI?
Request to speak with a representative

Important Safety Information and Indication

WARNINGS AND PRECAUTIONS

Dermatologic Adverse Reactions
Treatment with BRINSUPRI is associated with an increase in dermatologic adverse reactions, including rash, dry skin, and hyperkeratosis. Monitor patients for development of new rashes or skin conditions and refer patients to a dermatologist for evaluation of new dermatologic findings.

Gingival and Periodontal Adverse Reactions
Treatment with BRINSUPRI is associated with an increase in gingival and periodontal adverse reactions. Refer patients to dental care services for regular dental checkups while taking BRINSUPRI. Advise patients to perform routine dental hygiene.

Live Attenuated Vaccines
It is unknown whether administration of live attenuated vaccines during BRINSUPRI treatment will affect the safety or effectiveness of these vaccines. The use of live attenuated vaccines should be avoided in patients receiving BRINSUPRI.

ADVERSE REACTIONS

The most common adverse reactions ≥2% in the ASPEN trial included upper respiratory tract infection, headache, rash, dry skin, hyperkeratosis, and hypertension. The safety profile for adult patients with NCFB in WILLOW was generally similar to ASPEN, except for a higher incidence of gingival and periodontal adverse reactions.

Less Common Adverse Reactions

Liver Function Test Elevations
In ASPEN, there was an increase from baseline in average ALT, AST, and alkaline phosphatase levels at all time points from Week 4 through Week 56 in both BRINSUPRI 10 mg and 25 mg arms compared to placebo. The incidence of ALT >3X upper limit of normal (ULN) was 0%, 1.2%, and 0.9%; the incidence of AST >3X ULN was 0.2%, 0.3%, and 0.5%; and the incidence of alkaline phosphatase >1.5X ULN was 2.5%, 4.1%, and 4.0% in patients treated with placebo and BRINSUPRI 10 mg and 25 mg, respectively.

Skin Cancers
In ASPEN, the incidence of skin cancers among patients treated with BRINSUPRI 10 mg and 25 mg was 0.5% and 1.9%, respectively, compared to 1.1% in placebo-treated patients.

Alopecia
In ASPEN, the incidence of alopecia among patients treated with BRINSUPRI 10 mg and 25 mg was 1.5% and 1.6% respectively, compared to 0.4% in placebo-treated patients.

USE IN SPECIFIC POPULATIONS

Pregnancy: There are no clinical data on the use of BRINSUPRI in pregnant women.

Lactation: There is no information regarding the presence of BRINSUPRI and/or its metabolite(s) in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for BRINSUPRI and any potential adverse effects on the breastfed child from BRINSUPRI or from the underlying maternal condition.

Pediatric use: The safety and effectiveness of BRINSUPRI for the treatment of NCFB have been established in pediatric patients aged 12 years and older. Common adverse reactions in pediatric patients aged 12 years and older enrolled in ASPEN were consistent with those in adults. The safety and effectiveness of BRINSUPRI have not been established in pediatric patients younger than 12 years of age.

INDICATION

BRINSUPRI is indicated for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult and pediatric patients 12 years of age and older.

Please see full Prescribing Information.

Important Safety Information and Indication

WARNINGS AND PRECAUTIONS

Dermatologic Adverse Reactions
Treatment with BRINSUPRI is associated with an increase in dermatologic adverse reactions, including rash, dry skin, and hyperkeratosis. Monitor patients for development of new rashes or skin conditions and refer patients to a dermatologist for evaluation of new dermatologic findings.

Gingival and Periodontal Adverse Reactions
Treatment with BRINSUPRI is associated with an increase in gingival and periodontal adverse reactions. Refer patients to dental care services for regular dental checkups while taking BRINSUPRI. Advise patients to perform routine dental hygiene.

Live Attenuated Vaccines
It is unknown whether administration of live attenuated vaccines during BRINSUPRI treatment will affect the safety or effectiveness of these vaccines. The use of live attenuated vaccines should be avoided in patients receiving BRINSUPRI.

ADVERSE REACTIONS

The most common adverse reactions ≥2% in the ASPEN trial included upper respiratory tract infection, headache, rash, dry skin, hyperkeratosis, and hypertension. The safety profile for adult patients with NCFB in WILLOW was generally similar to ASPEN, except for a higher incidence of gingival and periodontal adverse reactions.

Less Common Adverse Reactions

Liver Function Test Elevations
In ASPEN, there was an increase from baseline in average ALT, AST, and alkaline phosphatase levels at all time points from Week 4 through Week 56 in both BRINSUPRI 10 mg and 25 mg arms compared to placebo. The incidence of ALT >3X upper limit of normal (ULN) was 0%, 1.2%, and 0.9%; the incidence of AST >3X ULN was 0.2%, 0.3%, and 0.5%; and the incidence of alkaline phosphatase >1.5X ULN was 2.5%, 4.1%, and 4.0% in patients treated with placebo and BRINSUPRI 10 mg and 25 mg, respectively.

Skin Cancers
In ASPEN, the incidence of skin cancers among patients treated with BRINSUPRI 10 mg and 25 mg was 0.5% and 1.9%, respectively, compared to 1.1% in placebo-treated patients.

Alopecia
In ASPEN, the incidence of alopecia among patients treated with BRINSUPRI 10 mg and 25 mg was 1.5% and 1.6% respectively, compared to 0.4% in placebo-treated patients.

USE IN SPECIFIC POPULATIONS

Pregnancy: There are no clinical data on the use of BRINSUPRI in pregnant women.

Lactation: There is no information regarding the presence of BRINSUPRI and/or its metabolite(s) in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for BRINSUPRI and any potential adverse effects on the breastfed child from BRINSUPRI or from the underlying maternal condition.

Pediatric use: The safety and effectiveness of BRINSUPRI for the treatment of NCFB have been established in pediatric patients aged 12 years and older. Common adverse reactions in pediatric patients aged 12 years and older enrolled in ASPEN were consistent with those in adults. The safety and effectiveness of BRINSUPRI have not been established in pediatric patients younger than 12 years of age.

INDICATION

BRINSUPRI is indicated for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult and pediatric patients 12 years of age and older.

Please see full Prescribing Information.